IRIS
FURFARO, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 421
EU - Europa 373
NA - Nord America 224
SA - Sud America 82
AF - Africa 2
Totale 1.102
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 261
US - Stati Uniti d'America 214
SE - Svezia 105
BR - Brasile 78
IT - Italia 78
CN - Cina 76
HK - Hong Kong 61
RU - Federazione Russa 52
DE - Germania 43
FI - Finlandia 36
GB - Regno Unito 18
AT - Austria 13
NL - Olanda 11
CA - Canada 6
IN - India 4
MX - Messico 4
BE - Belgio 3
ES - Italia 3
IQ - Iraq 3
UA - Ucraina 3
EC - Ecuador 2
ID - Indonesia 2
IE - Irlanda 2
IR - Iran 2
KW - Kuwait 2
PT - Portogallo 2
TW - Taiwan 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
FR - Francia 1
IL - Israele 1
JO - Giordania 1
JP - Giappone 1
KE - Kenya 1
LB - Libano 1
LT - Lituania 1
MA - Marocco 1
MY - Malesia 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 1.102
Salva come PNG Salva come JPEG
Città #
Shanghai 60
Lawrence 58
Princeton 58
Singapore 56
Hong Kong 55
Helsinki 34
Moscow 30
Ashburn 29
Milan 23
New York 12
Falkenstein 9
Slough 9
Nuremberg 7
Vienna 7
Brescia 5
London 5
Messina 5
Phoenix 5
Saint Louis 5
Hyderabad 4
Amsterdam 3
Bari 3
Belo Horizonte 3
Borås 3
Brussels 3
Catania 3
Frankfurt am Main 3
Malmo 3
Ottawa 3
Rome 3
Seattle 3
São Paulo 3
Bologna 2
Brasília 2
Cesano Boscone 2
Dourados 2
Dublin 2
Duque de Caxias 2
Genoa 2
Hangzhou 2
Indaiatuba 2
Kuwait City 2
Linköping 2
Lviv 2
Motala 2
Munich 2
Naples 2
New Taipei City 2
Oggiono 2
Pamplona 2
Porto Alegre 2
Praia Grande 2
Prineville 2
Quiliano 2
Quito 2
Salvador 2
Siziano 2
Sorocaba 2
São João da Madeira 2
Turin 2
Amman 1
Ann Arbor 1
Apiaí 1
Assaí 1
Baku 1
Banjarmasin 1
Belford Roxo 1
Belo Campo 1
Boardman 1
Bragança Paulista 1
Cabo Frio 1
Campinas do Sul 1
Campo Bom 1
Campo Magro 1
Candelária 1
Cantagalo 1
Caracas 1
Castellón 1
Caxias do Sul 1
Chuhuiv 1
Coatzacoalcos 1
Colombo 1
Couto de Magalhães de Minas 1
Cuiabá 1
Curitiba 1
Erbil 1
Espírito Santo 1
Florence 1
Florianópolis 1
Fortaleza 1
Franca 1
Frontera 1
George Town 1
Goiânia 1
Guanambi 1
Guarujá 1
Ipatinga 1
Itaguaí 1
Itaquaquecetuba 1
Jerusalem 1
Totale 608
Salva come PNG Salva come JPEG
Nome #
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial 40
Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease 39
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience 38
y ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE 25
JAK inhibitors: Novel developments in management of ulcerative colitis 24
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 24
Psychological Functioning of Patients With Inflammatory Bowel Disease 22
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 21
BOWEL ULTRASOUND IS ACCURATE IN ASSESSING DISEASE ACTIVITY IN ULCERATIVE COLITIS 20
Point-of-Care Ultrasound in Inflammatory Bowel Disease 20
SWITCHING FROM INFLIXIMAB ORIGINATOR TO CT-P13 IS NOT RELATED TO INCREASED IMMUNOGENICITY IN IBD PATIENTS: A PROSPECTIVE CASE-CONTROL STUDY 19
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease 19
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 19
Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho study 18
Targeting the gut layers in Crohn's disease: mucosal or transmural healing? 18
Risk Factor Analysis for Therapy Related Adverse Events and Infections in Elder Patients With Inflammatory Bowel Disease; An Analysis From the iG-IBD Aged Study 17
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts 17
Illness perception in IBD patients: a prospective study 16
Bowel ultrasound is accurate in assessing disease activity in ulcerative colitis 16
Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study 16
Can IL-23 be a good target for ulcerative colitis? 16
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 16
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men 16
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 16
Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach 16
COMPARATIVE ACCURACY OF US VERSUS MRI AND COLONOSCOPY IN ASSESSING DISEASE ACTIVITY AND COMPLICATIONS AND INFLUENCING THE DECISION-MAKING PROCESS IN CROHN'S DISEASE 16
STIMULATION OF CYP450-MEDIATED omega-3 DOCOSAHEXAENOIC ACID (DHA) METABOLISM VIA MFSD2A AS A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE 15
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 15
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 15
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 15
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease 14
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 14
Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study 14
Improving quality of care in endoscopy of inflammatory bowel disease: can we do better? 14
Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners 14
Modulation of sphingosine-1-phosphate in ulcerative colitis 14
Emerging therapeutic targets and strategies in Crohn's disease 14
Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease 14
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic 14
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration 14
The safety of biological pharmacotherapy for the treatment of ulcerative colitis 13
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of C-13-urea 13
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making 13
Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA 12
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience 12
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block 12
Detection and management of early stage inflammatory bowel disease: an update for clinicians 12
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 12
Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease? 12
Milan Ultrasound Criteria are accurate in assessing disease activity in ulcerative colitis: External validation 12
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis 12
Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile 12
Advancing Colorectal Cancer Prevention in Inflammatory Bowel Disease (IBD): Challenges and Innovations in Endoscopic Surveillance 11
Stimulation of CYP450-mediated omega-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease 11
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy 11
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 11
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study 11
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients 11
Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study 10
RAPID DETECTION OF ANTI-INFLIXIMAB ANTIBODIES IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13: PERFORMANCE COMPARISON WITH ELISA 10
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience 10
Biosimilars of adalimumab: the upcoming challenge in IBD 9
Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art 7
Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era 6
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches 6
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease 5
Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis 5
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study 5
New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients 5
Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question 4
The Role of IL-23 Inhibitors in Crohn’s Disease 4
Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors 4
Neutrophil-only Histological Assessment of Ulcerative Colitis Correlates with Endoscopic Activity and Predicts Long-Term Outcomes in a Multicentre Study 4
Multiple Ileal and Colonic Stenoses: Is It Always Crohn’s Disease? 4
Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease 4
Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future 4
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 4
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures 4
Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality? 4
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 4
ASSESSMENT OF THE DISEASE EXTENSION IN CHILDREN AND ADOLESCENTS WITH IBD: COMPARISON OF BOWEL ULTRASOUND AND MAGNETIC RESONANCE ENTEROGRAPHY 4
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 4
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 4
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study 4
Carcinomas in inflammatory bowel disease: a narrative review on diagnostic imaging techniques 4
Inflammatory Bowel Disease and Colorectal Cancer 4
A Comprehensive Multidisciplinary Approach to Diagnosing Chronic Inflammatory Bowel Diseases: Integration of Clinical, Endoscopic, and Imaging Modalities 4
Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis 4
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 4
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 4
Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease 3
Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases 3
Raising the bar in ulcerative colitis management 3
IBD Flare in the COVID-19 Pandemic:Therapy Discontinuation Is to Blame 3
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 3
Splanchnic Hemodynamics and Intestinal Vascularity in Crohn's Disease: An In Vivo Evaluation Using Doppler and Contrast-Enhanced Ultrasound and Biochemical Parameters 3
Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis 3
Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis 3
The Role of Fecal Microbiota Transplantation in IBD 3
Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment 3
Totale 1.149
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.331
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.331
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202292 0 0 0 73 1 5 0 1 0 2 5 5
2022/2023252 149 36 9 2 1 25 10 9 8 2 0 1
2023/202461 1 3 2 0 4 16 3 6 0 0 2 24
2024/2025895 106 8 13 3 1 56 134 303 271 0 0 0
Totale 1.300